UNSPSC 51392002: Adibendan

This classification denotes a phosphodiesterase inhibitor with the molecular formula C16H14N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E87N3L27KX, chemically known as 5,7-dihydro-7,7-dimethyl-2-(4-pyridyl)pyrrolo(2,3-f)benzimidazol-6(3h)-one but generally known as adibendan, which bears US NIH Compound Identifier 65867. European Medicines Agency schedules Adibendan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05268MIG.

UNSPSC 51392002 Adibendan is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The two recent opportunities tagged under this code diverge significantly from pharmaceutical intermediate products: Seminole County, Florida is procuring naloxone and safe drug deactivation systems through an IFB posted June 30, 2026, with a response deadline of July 26, 2023, while the Texas Health and Human Services Commission issued an RFI on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment programs. Neither solicitation targets adibendan specifically or reflects the chemical compound's typical pharmaceutical or industrial applications. The Seminole County opportunity requires 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and includes insurance, drug-free workplace, and E-Verify compliance requirements. The Texas HHS RFI seeks vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program without a formal competitive timeline or budget allocation at that preliminary stage.

Recent state and local opportunities show activity concentrated in Florida and Texas, though the adibendan code itself appears to receive limited direct procurement volume. The Seminole County IFB represents a concrete, near-term opportunity with a fixed-fee award structure and a two-year initial term with one-year renewal option, though the naloxone and drug deactivation systems procurement is only tangentially related to the code's nominal pharmaceutical intermediate classification. The Texas RFI functions as exploratory market research rather than a binding solicitation and does not signal imminent procurement under this code. No other state or local jurisdictions appear in the recent-opportunities block, and no repeat buyers or geographic concentration emerge from the available data.